Table 2.

Summary of outcomes. (A) Study groups—all immunosuppression treated groups included a steroid taper over a course of 1 month. Animals that were sacrificed due to viral illness and failure to thrive did not demonstrate gross abnormalities on pathologic evaluation. (B) Historical controls previously published (13)

(A) Group and regimen*	Animal ID	Initial visual changes prior to biopsy (POD)	Biopsy (POD)	Banff grade	Study endpoint	DSA (Y/N)
Allograft control	Allo1	2			rejection	N/A
No immunosupresion	Allo2	5			rejection	N/A
Autograft control	Auto1	negative	N/A	–	survival	N/A
No immunosuppression	Auto2	negative	N/A	–	survival	N/A
	Auto3	negative	N/A	–	survival	N/A
Group I	T1	14	15	1	rejection	Y
Tacrolimus	T2	7	7	1	rejection	N
	T3	13	14	2	rejection	N
Group II	CAS1	14	14	N/A	graft failure	N
CTLA-4Ig, alefacept, sirolimus	CAS2	5	9	N/A	graft failure	N
Group III	CAT1	56	62	1	rejection	N
CTLA-4Ig, alefacept, tacrolimus with conversion to sirolimus	CAT2	63	63	1	rejection	N
	CAT3	none	41	0	failure to thrive (cuthanasia)	N
	CAT4	none	65	0	failure to thrive (cuthanasia)	N
	CAT5	84	92	3	rejection	N
	CAT6	42	49	3	rejection	N
Group IV	BAT1	none	56	0	failure to thrive (cuthanasia)	N
Belatacept, alefacept, tacrolimus with sirolimus conversion	BAT2	85	90	3	rejection	N
	BAT3	none	73	0	failure to thrive (cuthanasia)	N
	BAT4	21	21	2	rejection	N
Group V	BAT1	28	28	2	rejection	N
Belatacept, tacrolimus with sirolimus conversion	BAT2	none	77	1	failure to thrive (cuthanasia)	N
	BAT3	98	133	3	rejection	N
	BAT4	112	140	3	rejection	N

(B) Group and regimen*	Animal ID	Day of rejection	Donor specific antibody (Y/N)
1. DSA, donor-specific antibody; MMF, mycophenolate mofetil; POD, postoperative day.
Allograft controls without immunosuppression	Hist1	3	Y
	Hist2	4	N
	Hist3	4	N
	Hist4	3	N/A
	Hist5	7	Y
	Hist6	4	Y
	Hist7	8	Y
Triple therapy (tacrolimus, MMF, and steroid taper)	Hist8	15	Y
	Hist9	5	N
	Hist10	17	Y
	Hist11	24	Y
	Hist12	8	Y
	Hist13	73	Y
	Hist14	76	Y